PUBLICATION

Global Business Reports

AUTHORS

Lorena Stancu, Mariolga Guyon, Maria Filippova

Italy Life Sciences 2021 - Digital Version

October 12, 2021

The Italian life sciences industry is driven by two main forces: A competitive manufacturing power, with particularly large API capabilities that produce 9% of the world’s ingredients; and a diverse and fragmented biotech sector with excellent scientific credentials. While the former has been a major growth pillar of the last few decades, the latter could pave the way for a research-driven Italian industry for the decades to come.

The pandemic has been a catalytic event for Italy’s life sciences industries: Demand and supply have struggled to fall into balance, the M&A space witnessed record-setting transactions, and the healthcare system itself has become an investment priority at both national and European levels.

In this inaugural Italy Life Sciences report, we analyze how Italy can correct some of the structural issues that the pandemic exposed, and we address the role that digital health could play in a remote consultation and remote disease monitoring setup.

Section 2 is focused on Italy’s manufacturing base. We profile Italy’s homegrown pharma and we provide a framework to understand market access and pricing for foreign companies. We then look specifically at the strengths of Italy’s staple CDMO segment, as well as checking the socio-demographic dynamics in the non-prescription segment.

The final part of the book is dedicated to innovation exploring the drivers and inhibitors across the route from drug discovery to commercialization. We also examine the ideas stemming from innovative minds, especially when these minds collaborate. In our “Therapies and Diagnostics” article, we study the current state of both cancer diagnostics and treatment, as well as the unique context of orphan drugs.

RELATED INTERVIEWS MORE INTERVIEWS

Lisapharma describes the challenges Italian pharma producers have experienced over the past two years.
NMS is one of the largest kinase inhibitors-focused oncology drug discovery companies in Italy.
Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.

MACIG

"The firm specializes in the dynamic field of sustainability law, focusing on environmental law, energy law, mining law and policy, and occupational and mine health and safety law."

SUBSCRIBE TO OUR NEWSLETTER